Alkermes Advances Narcolepsy Drug into Phase 3 Trials
Event summary
- Alkermes initiated Phase 3 Brilliance Studies for alixorexton, evaluating its safety and efficacy in narcolepsy Type 1 and Type 2.
- The program includes three 12-week studies: two for NT1 (Studies 302 and 304) and one for NT2 (Study 303).
- Primary endpoint measures increase in wakefulness via the Maintenance of Wakefulness Test (MWT).
- Alixorexton has received Breakthrough Therapy designation from the FDA for NT1 treatment.
- Studies will enroll approximately 150 patients for NT1 and 180 for NT2 across North America, Asia Pacific, and Europe.
The big picture
Alkermes' Phase 3 trials for alixorexton mark a critical step in expanding treatment options for narcolepsy, a market dominated by established therapies. The focus on orexin 2 receptor agonism reflects a broader industry shift toward targeting wakefulness pathways. Success could position Alkermes as a key player in the hypersomnolence disorder space, potentially unlocking new revenue streams beyond its existing neuroscience portfolio.
What we're watching
- Clinical Efficacy
- Whether alixorexton demonstrates superior wakefulness improvement over placebo in Phase 3 trials.
- Regulatory Pathway
- The pace at which the FDA reviews alixorexton data, given its Breakthrough Therapy designation.
- Market Differentiation
- How Alkermes positions alixorexton against existing narcolepsy treatments like Xyrem and Sunosi.